Gut microbiota in non‐alcoholic fatty liver disease and alcohol‐related liver disease: Current concepts and perspectives

Juan P. Arab,Marco Arrese,Vijay H. Shah
DOI: https://doi.org/10.1111/hepr.13473
2020-04-01
Hepatology Research
Abstract:The term gut‐liver axis is used to highlight the close anatomical and functional relationship between the intestine and the liver. It has been increasingly recognized that the gut‐liver axis plays an essential role in the development and progression of liver disease. In particular, in non‐alcoholic fatty liver disease (NAFLD) and alcohol‐related liver disease (ALD), the two most common causes of chronic liver disease, a dysbiotic gut microbiota can influence intestinal permeability allowing some pathogens or bacteria‐derived factors from the gut reaching the liver via the enterohepatic circulation contributing to liver injury, steatohepatitis and fibrosis progression. Pathways involved are multiple, including changes in bile acid metabolism, intestinal ethanol production, generation of short‐chain fatty acids, and other by‐products. Bile acids act through dedicated bile acid receptors farnesoid X receptor and TGR5 in both the ileum and the liver, influencing lipid metabolism, inflammation, and fibrogenesis. Currently, both NAFLD and ALD lack of effective therapies and therapeutic targeting of gut microbiota and bile acids enterohepatic circulation hold promise. In this review, we summarize current knowledge about the role of gut microbiota in the pathogenesis of NAFLD and ALD, as well as the relevance of microbiota or bile acid‐based approaches in the management of those liver diseases.
gastroenterology & hepatology
What problem does this paper attempt to address?